Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Head and Neck 100: Avelumab + CRT in LA SCCHN
NCT02952586Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Avelumab + SoC CRT with Placebo + SoC CRT (2 arms). Primary endpoint: Progression-free Survival at 37 months. Started Nov 2016; status: terminated.
02
Drugs
avelumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02952586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952586.